RxDoctor Payments Data

Amy Agena, PA

Medical · Lincoln, NENPI 1114195526

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 44.6% of the total.

$3,427in general payments, 2019–2025

Across 216 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$549
  • Lilly USA, LLC$147
  • Astellas Pharma US Inc$120
  • AstraZeneca$117
  • Bayer$112
  • plus $851 from 27 others

What the payments were for

  • Food & beverage$3,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,427 in reported general payments places this provider in the 85th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska

Medicare billing

Part B allowed, 2024
$25,032
Medicare patients
123
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban20$22,762
TrulicityDulaglutide20$19,356
OzempicSemaglutide19$17,902
MyrbetriqMirabegron28$13,007
FarxigaDapagliflozin Propanediol13$9,240
Breo ElliptaFluticasone/Vilanterol13$5,330
DayvigoLemborexant14$4,647
Duloxetine Hcl86$1,505
Gabapentin66$1,406
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$1,120
Levothyroxine Sodium128$1,118
Colchicine11$951
Omeprazole98$933
Nebivolol Hcl12$747
Pantoprazole Sodium54$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$40$22,76220 claims
Lilly USA, LLCTrulicity$147$19,35620 claims
Novo NordiskOzempic$549$17,90219 claims
Astellas Pharma US IncMyrbetriq$120$13,00728 claims
AstraZenecaFarxiga$117$9,24013 claims
GSKBreo Ellipta$15$5,33013 claims
Eisai Inc.Dayvigo$14$4,64714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 216 medical providers in Nebraska.

Other medical in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →